Your browser doesn't support javascript.
loading
Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV.
Rechtien, Anne; Richert, Laura; Lorenzo, Hadrien; Martrus, Gloria; Hejblum, Boris; Dahlke, Christine; Kasonta, Rahel; Zinser, Madeleine; Stubbe, Hans; Matschl, Urte; Lohse, Ansgar; Krähling, Verena; Eickmann, Markus; Becker, Stephan; Thiébaut, Rodolphe; Altfeld, Marcus; Addo, Marylyn M.
Afiliação
  • Rechtien A; University Medical Center Hamburg-Eppendorf, 1(st) Department of Medicine, 20246 Hamburg, Germany; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, 20246 Hamburg, Germany; Heinrich Pette Institute, Leibniz Institute for Experimental Virology, 20251 Hamburg, Ger
  • Richert L; Heinrich Pette Institute, Leibniz Institute for Experimental Virology, 20251 Hamburg, Germany; INSERM U1219, INRIA SISTM, Bordeaux University, Bordeaux, France; Vaccine Research Institute, Creteil, France.
  • Lorenzo H; INSERM U1219, INRIA SISTM, Bordeaux University, Bordeaux, France; Vaccine Research Institute, Creteil, France.
  • Martrus G; Heinrich Pette Institute, Leibniz Institute for Experimental Virology, 20251 Hamburg, Germany.
  • Hejblum B; INSERM U1219, INRIA SISTM, Bordeaux University, Bordeaux, France; Vaccine Research Institute, Creteil, France.
  • Dahlke C; University Medical Center Hamburg-Eppendorf, 1(st) Department of Medicine, 20246 Hamburg, Germany; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, 20246 Hamburg, Germany.
  • Kasonta R; University Medical Center Hamburg-Eppendorf, 1(st) Department of Medicine, 20246 Hamburg, Germany; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, 20246 Hamburg, Germany.
  • Zinser M; University Medical Center Hamburg-Eppendorf, 1(st) Department of Medicine, 20246 Hamburg, Germany.
  • Stubbe H; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, 20246 Hamburg, Germany; Division of Infectious Diseases, Department of Medicine IV, LMU, 80336 Munich, Germany.
  • Matschl U; Heinrich Pette Institute, Leibniz Institute for Experimental Virology, 20251 Hamburg, Germany.
  • Lohse A; University Medical Center Hamburg-Eppendorf, 1(st) Department of Medicine, 20246 Hamburg, Germany.
  • Krähling V; Philipps University Marburg, Institute for Virology, 35043 Marburg, Germany.
  • Eickmann M; Philipps University Marburg, Institute for Virology, 35043 Marburg, Germany.
  • Becker S; Philipps University Marburg, Institute for Virology, 35043 Marburg, Germany.
  • Thiébaut R; INSERM U1219, INRIA SISTM, Bordeaux University, Bordeaux, France; Vaccine Research Institute, Creteil, France.
  • Altfeld M; Heinrich Pette Institute, Leibniz Institute for Experimental Virology, 20251 Hamburg, Germany.
  • Addo MM; University Medical Center Hamburg-Eppendorf, 1(st) Department of Medicine, 20246 Hamburg, Germany; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, 20246 Hamburg, Germany. Electronic address: ma.ddo@uke.de.
Cell Rep ; 20(9): 2251-2261, 2017 08 29.
Article em En | MEDLINE | ID: mdl-28854372
ABSTRACT
Predicting vaccine efficacy remains a challenge. We used a systems vaccinology approach to identify early innate immune correlates of antibody induction in humans receiving the Ebola vaccine rVSV-ZEBOV. Blood samples from days 0, 1, 3, 7, and 14 were analyzed for changes in cytokine levels, innate immune cell subsets, and gene expression. Integrative statistical analyses with cross-validation identified a signature of 5 early innate markers correlating with antibody titers on day 28 and beyond. Among those, IP-10 on day 3 and MFI of CXCR6 on NK cells on day 1 were independent correlates. Consistently, we found an early gene expression signature linked to IP-10. This comprehensive characterization of early innate immune responses to the rVSV-ZEBOV vaccine in humans revealed immune signatures linked to IP-10. These results suggest correlates of vaccine-induced antibody induction and provide a rationale to explore strategies for augmenting the effectiveness of vaccines through manipulation of IP-10.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinação / Vacinas contra Ebola / Imunidade Inata / Formação de Anticorpos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinação / Vacinas contra Ebola / Imunidade Inata / Formação de Anticorpos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article